Drug Approval
Santhera, ReveraGen’s Duchenne Drug Accepted By EMA While Anticipating FDA Priority Review
2022-11-01
Mounting Criticisms of FDA’s Accelerated Approval Pathway Could Prompt Changes to the System
2022-08-25